HUNTERSVILLE, N.C. , Nov. 18, 2025 /PRNewswire/ -- BioCytics is pleased to announce they successfully reached a regulatory milestone for de-risking clinical development plans with a productive FDA INTERACT meeting during which they discussed manufacturing immune cell therapies at the point of care.

This INTERACT ( IN itial T argeted E ngagement for R egulatory A dvice on C BER/CDER Produc T s) meeting is a first step in getting feedback from the FDA regarding the feasibility of BioCytics' cell therapy platform development plans. By accepting this meeting and reviewing the plans, the FDA is indicating that BioCytics' immuno-oncology tumor treatment protocol efforts, the first of which is called BioCytics Immune Fraction #1 (BCyIF-1), show enough pre-clinical scientific potential to warrant

See Full Page